{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:49:30Z","timestamp":1769276970918,"version":"3.49.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite major advances, multiple myeloma (MM) remains an incurable malignancy. Recently we have found that disease stabilization was achieved in 64% of patients with advanced MM treated with the farnesyltransferase inhibitor R115777 (Zarnestra) in a phase 2 clinical trial. In order to enhance R115777 antitumor activity in MM, we examined the combination of this novel agent with other anticancer drugs in MM cell lines. In this study, R115777 was found to synergize with paclitaxel and docetaxel, but not with other chemotherapy agents, including doxorubicin, 5-fluorouracil, cisplastin, melphalan, mitoxantrone, and dexamethasone. R115777 synergized with paclitaxel to inhibit MM cell proliferation and to induce apoptosis. Synergism in the induction of apoptosis was accompanied by increase in cytochrome c release and caspase-3 activation. Furthermore, flow cytometry analysis also showed that paclitaxel and R115777 synergized to induce G2\/M cell-cycle arrest. Importantly, synergism was observed in taxane- and R115777-resistant MM cells. In the human severe combined immunodeficient (SCID-hu) bone model of myeloma growth, the ability of paclitaxel to inhibit tumor growth in vivo was enhanced by R115777. Combination of paclitaxel or docetaxel with R115777 in the treatment of MM cells from patients with multiple myeloma was more beneficial than treatment with single agents. Our results provide the basis for combination therapy clinical trials with paclitaxel or docetaxel with R115777 in MM patients. (Blood. 2005;105:4759-4766)<\/jats:p>","DOI":"10.1182\/blood-2004-11-4307","type":"journal-article","created":{"date-parts":[[2005,2,23]],"date-time":"2005-02-23T04:44:02Z","timestamp":1109133842000},"page":"4759-4766","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells"],"prefix":"10.1182","volume":"105","author":[{"given":"Kuichun","family":"Zhu","sequence":"first","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Gerbino","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrin M.","family":"Beaupre","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Mackley","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Muro-Cacho","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Beam","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias G.","family":"Lichtenheld","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Kerr","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Dalton","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai\u0308d M.","family":"Sebti","sequence":"additional","affiliation":[{"name":"From the Drug Discovery Program, the Experimental Therapeutics Program and Immunology Program, Biostatistics Core, H. Lee Moffitt Cancer Center & Research Institute and the Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, FL; the Department of Microbiology and Immunology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; and Yale University, Department of Chemistry, New Haven, CT."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021223494502700_REF1","doi-asserted-by":"crossref","unstructured":"Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med.1997;336: 1657-1664.","DOI":"10.1056\/NEJM199706053362307"},{"key":"2020021223494502700_REF2","doi-asserted-by":"crossref","unstructured":"Bezieau S, Devilder MC, Avet-Loiseau H, et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat.2001;18: 212-224.","DOI":"10.1002\/humu.1177"},{"key":"2020021223494502700_REF3","doi-asserted-by":"crossref","unstructured":"Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group phase III trial. Blood.1996;88: 2699-2706.","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699"},{"key":"2020021223494502700_REF4","unstructured":"Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs.2003;4: 1428-1435."},{"key":"2020021223494502700_REF5","doi-asserted-by":"crossref","unstructured":"Johnston SR, Hickish T, Houston S, Ellis PA, Howes AJ, Thibault A. Efficacy and tolerability of two dosing regimens of R115777 (R115777), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer [abstract]. ASCO. 2002; 138.","DOI":"10.1200\/JCO.2003.10.064"},{"key":"2020021223494502700_REF6","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Cortes J, Kantarjian H. Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. Semin Hematol.2002;39: 20-24.","DOI":"10.1053\/shem.2002.36925"},{"key":"2020021223494502700_REF7","doi-asserted-by":"crossref","unstructured":"Alsina M, Fonseca R, Wilson EF, et al. Farnesyl-transferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic\/tumor survival pathways in patients with advanced multiple myeloma. Blood.2004;103: 3271-3277.","DOI":"10.1182\/blood-2003-08-2764"},{"key":"2020021223494502700_REF8","doi-asserted-by":"crossref","unstructured":"Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood.1997;90: 754-765.","DOI":"10.1182\/blood.V90.2.754"},{"key":"2020021223494502700_REF9","doi-asserted-by":"crossref","unstructured":"Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood.2003;101: 1530-1534.","DOI":"10.1182\/blood-2002-08-2543"},{"key":"2020021223494502700_REF10","doi-asserted-by":"crossref","unstructured":"Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase\/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol.2000;20: 139-148.","DOI":"10.1128\/MCB.20.1.139-148.2000"},{"key":"2020021223494502700_REF11","doi-asserted-by":"crossref","unstructured":"Kyoizumi S, Baum CM, Kaneshima H, McCune JM, Yee EJ, Namikawa R. Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood.1992;79: 1704-1711.","DOI":"10.1182\/blood.V79.7.1704.1704"},{"key":"2020021223494502700_REF12","doi-asserted-by":"crossref","unstructured":"Solar GP, Kerr WG, Zeigler FC, et al. Role of c-mpl in early hematopoiesis. Blood.1998;92: 4-10.","DOI":"10.1182\/blood.V92.1.4.413k38_4_10"},{"key":"2020021223494502700_REF13","unstructured":"Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther.2001;298: 865-872."},{"key":"2020021223494502700_REF14","unstructured":"Bishop YMM, Fienberg SE, Holland PW. Discrete Multivariate Analysis: Theory and Practice. Cambridge, MA: The MIT Press; 1975."},{"key":"2020021223494502700_REF15","unstructured":"Altman DG. Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall\/CRC; 1991."},{"key":"2020021223494502700_REF16","unstructured":"Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res.1996;56: 816-825."},{"key":"2020021223494502700_REF17","doi-asserted-by":"crossref","unstructured":"Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med.1995;1: 506-526.","DOI":"10.1007\/BF03401588"},{"key":"2020021223494502700_REF18","doi-asserted-by":"crossref","unstructured":"Seidman AD, Tiersten A, Hudis C, et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol.1995;13: 2575-2581.","DOI":"10.1200\/JCO.1995.13.10.2575"},{"key":"2020021223494502700_REF19","doi-asserted-by":"crossref","unstructured":"Rischin D, Ackland SP, Smith J, et al. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann Oncol.2002;13: 1810-1818.","DOI":"10.1093\/annonc\/mdf305"},{"key":"2020021223494502700_REF20","doi-asserted-by":"crossref","unstructured":"Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood.2001;97: 3361-3369.","DOI":"10.1182\/blood.V97.11.3361"},{"key":"2020021223494502700_REF21","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood.2003;102: 4527-4534.","DOI":"10.1182\/blood-2002-11-3359"},{"key":"2020021223494502700_REF22","doi-asserted-by":"crossref","unstructured":"Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A.1998;95: 1369-1374.","DOI":"10.1073\/pnas.95.4.1369"},{"key":"2020021223494502700_REF23","unstructured":"Sun J, Blaskovich MA, Knowles D, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res.1999;59: 4919-4926."},{"key":"2020021223494502700_REF24","doi-asserted-by":"crossref","unstructured":"Sebti SM, Der CJ. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer.2003;3: 945-951.","DOI":"10.1038\/nrc1234"},{"key":"2020021223494502700_REF25","unstructured":"Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R. Implication of protein kinase B\/Akt and Bcl-2\/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res.2003;63: 4796-4800."},{"key":"2020021223494502700_REF26","unstructured":"MacKeigan JP, Taxman DJ, Hunter D, Earp HS III, Graves LM, Ting JP. Inactivation of the anti-apoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res.2002;8: 2091-2099."},{"key":"2020021223494502700_REF27","unstructured":"Asakuma J, Sumitomo M, Asano T, Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res.2003;63: 1365-1370."},{"key":"2020021223494502700_REF28","doi-asserted-by":"crossref","unstructured":"Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene.2001;20: 147-155.","DOI":"10.1038\/sj.onc.1204062"},{"key":"2020021223494502700_REF29","doi-asserted-by":"crossref","unstructured":"Seidman R, Gitelman I, Sagi O, Horwitz SB, Wolfson M. The role of ERK 1\/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res.2001;268: 84-92.","DOI":"10.1006\/excr.2001.5262"},{"key":"2020021223494502700_REF30","doi-asserted-by":"crossref","unstructured":"Dankbar B, Padro\u0301 T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood.2000;95: 2630-2636.","DOI":"10.1182\/blood.V95.8.2630"},{"key":"2020021223494502700_REF31","doi-asserted-by":"crossref","unstructured":"Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia.2001;15: 1950-1961.","DOI":"10.1038\/sj.leu.2402295"},{"key":"2020021223494502700_REF32","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia.2002;16: 1664-1667.","DOI":"10.1038\/sj.leu.2402629"},{"key":"2020021223494502700_REF33","doi-asserted-by":"crossref","unstructured":"Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer.2000;88: 2619-2628.","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J"},{"key":"2020021223494502700_REF34","unstructured":"Frenkel GD, Caffrey PB. A prevention strategy for circumventing drug resistance in cancer chemotherapy. Curr Pharm Des.2001;7: 1595-1614."},{"key":"2020021223494502700_REF35","unstructured":"Galmarini CM, Galmarini FC. Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs.2003;4: 1416-1421."},{"key":"2020021223494502700_REF36","doi-asserted-by":"crossref","unstructured":"Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia.2003;17: 451-457.","DOI":"10.1038\/sj.leu.2402832"},{"key":"2020021223494502700_REF37","unstructured":"Cloughesy TF, Kuhn J, Robins HI, et al. A phase 1 trial of R115777 in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs (EIAEDs): a North American Brain Tumor Consortium study. J Clin Oncol. In press."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/12\/4759\/1710324\/zh801205004759.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/12\/4759\/1710324\/zh801205004759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T04:50:00Z","timestamp":1581569400000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/12\/4759\/19684\/Farnesyltransferase-inhibitor-R115777-Zarnestra"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,15]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-11-4307","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,15]]}}}